Antonia I. Antoniou

Dr. Antonia I. Antoniou

Università degli Studi di Milano, Milan, Lombardy, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
AAAntonia I. Antoniou
Antonia I. Antoniou
SGSabrina Giofrè
Sabrina Giofrè
PSPierfausto Seneci
Pierfausto Seneci
DPDaniele Passarella
Daniele Passarella
sara pellegrinosara pellegrino
sara pellegrino

4 June 2014 in Organic Letters
Verified
Journal Article
Closed access
Maria ChatzopoulouMaria Chatzopoulou
Maria Chatzopoulou
AAAntonia I. Antoniou
Antonia I. Antoniou
EPEmmanuel N. Pitsinos
Emmanuel N. Pitsinos
MBMarina Bantzi
Marina Bantzi
SKSofia D. Koulocheri
Sofia D. Koulocheri
AGAthanassios Giannis
Athanassios Giannis

7 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SGSabrina Giofrè
Sabrina Giofrè
ARAntonio Renda
Antonio Renda
SSSilvia Sesana
Silvia Sesana
BFBeatrice Formicola
Beatrice Formicola
BVBarbara Vergani
Barbara Vergani
FRFrancesca Re
Francesca Re
Dual functionalized liposomes were developed to cross the blood–brain barrier (BBB) and to release their cargo in a pathological matrix metalloproteinase (MMP)-rich microenvironment. Liposomes were surface-functionalized with a modified peptide deriving from the receptor-binding domain of apolipoprotein E (mApoE), known to promote cargo delivery to the brain across the BBB in vitro and in vivo; and with an MMP-sensitive moiety for an MMP-triggered drug release. Different MMP-sensitive peptides were functionalized at both ends with hydrophobic stearate tails to yield MMP-sensitive lipopeptides (MSLPs), which were assembled into mApoE liposomes. The resulting bi-functional liposomes (i) displayed a < 180 nm diameter with a negative ζ-potential; (ii) were able to cross an in vitro BBB model with an endothelial permeability of 3 ± 1 × 10−5 cm/min; (iii) when exposed to functional MMP2 or 9, efficiently released an encapsulated fluorescein dye; (iv) showed high biocompatibility when tested in neuronal cultures; and (v) when loaded with glibenclamide, a drug candidate with poor aqueous solubility, reduced the release of proinflammatory cytokines from activated microglial cells.

3 May 2016 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
AAAntonia I. Antoniou
Antonia I. Antoniou
DPDionissia A. Pepe
Dionissia A. Pepe
Donatella AielloDonatella Aiello
Donatella Aiello
CSCarlo Siciliano
Carlo Siciliano
Constantinos AthanassopoulosConstantinos Athanassopoulos
Constantinos Athanassopoulos

2 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJerónimo Laiolo
Jerónimo Laiolo
DGDafni G. Graikioti
Dafni G. Graikioti
CBCecilia L. Barbieri
Cecilia L. Barbieri
MJMariana B. Joray
Mariana B. Joray
AAAntonia I. Antoniou
Antonia I. Antoniou
MCMaría Cecilia Carpinella
María Cecilia Carpinella
Chemotherapy is a powerful means of cancer treatment but its efficacy is compromised by the emergence of multidrug resistance (MDR), mainly linked to the efflux transporter ABCB1/P-glycoprotein (P-gp). Based on the chemical structure of betulin, identified in our previous work as an effective modulator of the P-gp function, a series of analogs were designed, synthesized and evaluated as a source of novel inhibitors. Compounds 6g and 6i inhibited rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox, at concentrations of 0.19 µM and 0.39 µM, respectively, and increased the intracellular accumulation of doxorubicin at the submicromolar concentration of 0.098 µM. Compounds 6g and 6i were able to restore the sensitivity of K562/Dox to Dox at 0.024 µM and 0.19 µM, respectively. Structure–activity relationship analysis and molecular modeling revealed important information about the structural features conferring activity. All the active compounds fitted in a specific region involving mainly transmembrane helices (TMH) 4–6 from one homologous half and TMH 7 and 12 from the other, also showing close contacts with TMH 6 and 12. Compounds that bound preferentially to another region were inactive, regardless of their free energy of binding. It should be noted that compounds 6g and 6i were devoid of toxic effects against peripheral blood mononuclear normal cells and erythrocytes. The data obtained indicates that both compounds might be proposed as scaffolds for obtaining promising P-gp inhibitors for overcoming MDR.

21 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
DPDespina Palla
Despina Palla
AAAntonia I. Antoniou
Antonia I. Antoniou
MBMichel Baltas
Michel Baltas
CMChristophe Menendez
Christophe Menendez
PGPhilippe Grellier
Philippe Grellier
Constantinos AthanassopoulosConstantinos Athanassopoulos
Constantinos Athanassopoulos
Malaria, despite many efforts, remains among the most problematic infectious diseases worldwide, mainly due to the development of drug resistance by Plasmodium falciparum. The antibiotic fosmidomycin (FSM) is also known for its antimalarial activity by targeting the non-mevalonate isoprenoid synthesis pathway, which is essential for the malaria parasites but is absent in mammalians. In this study, we synthesized and evaluated against the chloroquine-resistant P. falciparum FcB1/Colombia strain, a series of FSM analogs, derivatives, and conjugates with other antimalarial agents, such as artemisinin (ART) and aminochloroquinoline (ACQ). The biological evaluation revealed four new compounds with higher antimalarial activity than FSM: two FSM-ACQ derivatives and two FSM-ART conjugates, with 3.5–5.4 and 41.5–23.1 times more potent activities than FSM, respectively.